Trastuzumab--mechanism of action and use in clinical practice
- PMID: 17611206
- DOI: 10.1056/NEJMra043186
Trastuzumab--mechanism of action and use in clinical practice
Comment in
-
Trastuzumab--mechanism of action and use.N Engl J Med. 2007 Oct 18;357(16):1664; author reply 1665-6. doi: 10.1056/NEJMc072213. N Engl J Med. 2007. PMID: 17942884 No abstract available.
-
Trastuzumab--mechanism of action and use.N Engl J Med. 2007 Oct 18;357(16):1664-5; author reply 1665-6. N Engl J Med. 2007. PMID: 17948347 No abstract available.
Similar articles
-
The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1. Oncologist. 2004. PMID: 15163840 No abstract available.
-
[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x. Internist (Berl). 2006. PMID: 17048017 German. No abstract available.
-
Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.Expert Opin Biol Ther. 2007 Apr;7(4):487-91. doi: 10.1517/14712598.7.4.487. Expert Opin Biol Ther. 2007. PMID: 17373900 Review.
-
Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.BioDrugs. 2010 Jun;24(3):207-9. doi: 10.2165/11204680-000000000-00000. BioDrugs. 2010. PMID: 20462285 No abstract available.
-
[Herceptin (trastuzumab)].Gan To Kagaku Ryoho. 2007 Aug;34(8):1173-6. Gan To Kagaku Ryoho. 2007. PMID: 17687197 Review. Japanese.
Cited by
-
DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2+ breast cancer.J Immunother Cancer. 2024 Nov 14;12(11):e009636. doi: 10.1136/jitc-2024-009636. J Immunother Cancer. 2024. PMID: 39542653 Free PMC article.
-
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.Int J Mol Sci. 2024 Oct 31;25(21):11733. doi: 10.3390/ijms252111733. Int J Mol Sci. 2024. PMID: 39519282 Free PMC article.
-
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo.MAbs. 2024 Jan-Dec;16(1):2412881. doi: 10.1080/19420862.2024.2412881. Epub 2024 Oct 9. MAbs. 2024. PMID: 39381966 Free PMC article.
-
Theranostics in breast cancer.Front Nucl Med. 2023 Aug 4;3:1236565. doi: 10.3389/fnume.2023.1236565. eCollection 2023. Front Nucl Med. 2023. PMID: 39355052 Free PMC article. Review.
-
Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer.World J Gastrointest Oncol. 2024 Sep 15;16(9):3905-3912. doi: 10.4251/wjgo.v16.i9.3905. World J Gastrointest Oncol. 2024. PMID: 39350984 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical